These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 16153743)

  • 41. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
    Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gefitinib (IRESSA, ZD 1839) as a salvage treatment for patients with advanced non-small cell lung cancer.
    Jubelirer SJ; Yadwadkar KS; Kosowicz AB
    W V Med J; 2006; 102(6):14-7. PubMed ID: 17334161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programme.
    Ostoros G; Harisi R; Kovacs G; Horti J; Geczi L; Szondy K; Orosz M; Ferenczi E; Ruby E; Dome B
    Anticancer Res; 2005; 25(6C):4759-62. PubMed ID: 16334173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
    Araki J; Okamoto I; Suto R; Ichikawa Y; Sasaki J
    Lung Cancer; 2005 Apr; 48(1):141-4. PubMed ID: 15777982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
    Pizzo B
    Clin J Oncol Nurs; 2004 Aug; 8(4):385-92. PubMed ID: 15354925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.
    Nishio M; Ohyanagi F; Horiike A; Ishikawa Y; Satoh Y; Okumura S; Nakagawa K; Nishio K; Horai T
    Br J Cancer; 2005 May; 92(10):1877-80. PubMed ID: 15870715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
    Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Hirata K
    Osaka City Med J; 2012 Jun; 58(1):25-34. PubMed ID: 23094511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
    Bar J; Onn A
    Clin Lung Cancer; 2012 Jul; 13(4):267-79. PubMed ID: 22154113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer.
    Pircher A; Ulsperger E; Hack R; Jamnig H; Pall G; Zelger B; Sterlacci W; Hilbe W; Fiegl M
    Anticancer Res; 2011 Sep; 31(9):2949-55. PubMed ID: 21868543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
    Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
    Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
    Gangemi S; Franchina T; Minciullo PL; Profita M; Zanghì M; David A; Kennez I; Adamo V
    J Cell Biochem; 2013 Dec; 114(12):2673-6. PubMed ID: 23794184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program.
    Gridelli C; Rossi A; Maione P; Guerriero C; Airoma G; Colantuoni G; Barzelloni ML
    Anticancer Res; 2004; 24(3b):1873-7. PubMed ID: 15274368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
    Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
    Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
    Li J; Karlsson MO; Brahmer J; Spitz A; Zhao M; Hidalgo M; Baker SD
    J Natl Cancer Inst; 2006 Dec; 98(23):1714-23. PubMed ID: 17148773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
    Kakiuchi S; Daigo Y; Ishikawa N; Furukawa C; Tsunoda T; Yano S; Nakagawa K; Tsuruo T; Kohno N; Fukuoka M; Sone S; Nakamura Y
    Hum Mol Genet; 2004 Dec; 13(24):3029-43. PubMed ID: 15496427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
    Miller VA; Kris MG; Shah N; Patel J; Azzoli C; Gomez J; Krug LM; Pao W; Rizvi N; Pizzo B; Tyson L; Venkatraman E; Ben-Porat L; Memoli N; Zakowski M; Rusch V; Heelan RT
    J Clin Oncol; 2004 Mar; 22(6):1103-9. PubMed ID: 15020612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
    Yan Y; Lu Y; Wang M; Vikis H; Yao R; Wang Y; Lubet RA; You M
    Mol Cancer Res; 2006 Dec; 4(12):971-81. PubMed ID: 17189387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of gefitinib in non-small cell lung cancer treatment.
    Hsiue EH; Lee JH; Lin CC; Yang JC
    Expert Opin Drug Saf; 2016 Jul; 15(7):993-1000. PubMed ID: 27212579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
    Rukazenkov Y; Speake G; Marshall G; Anderton J; Davies BR; Wilkinson RW; Mark Hickinson D; Swaisland A
    Anticancer Drugs; 2009 Nov; 20(10):856-66. PubMed ID: 19657272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.